Nektar Therapeutics (NKTR) Tops Q2 EPS by 77c
Tweet
Share
E-mail
Get Alerts NKTR Hot Sheet
Price: $74.02 -0.68%
Financial Fact:
Total operating costs and expenses: 69.24M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Financial Fact:
Total operating costs and expenses: 69.24M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q2 EPS of ($1.23), $0.77 better than the analyst estimate of ($2.00). Revenue for the quarter came in at $10.13 million versus the consensus estimate of $10.38 million.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA maintains underperform ratings on six BDC stocks
- TD Cowen Assumes Nektar Therapeutics (NKTR) at Buy
- enVVeno Medical (NVNO) files $100M mixed shelf
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
